.jpg/:/cr=t:0%25,l:0%25,w:100%25,h:100%25/rs=h:100/fx-gs){kind=logo}
The Numbers
70 Million
3.4 Million
3.4 Million
People with Epilepsy Worldwide
3.4 Million
3.4 Million
3.4 Million
People with Epilepsy in the USA
150,000
3.4 Million
150,000
New Cases Annually in the USA
The PROBLEM
"Endless" Titration Loop
Physicians rely on self reported seizure data to manage their patient's epilepsy - particularly in determining the right medication and the right dose. However, studies have shown that this data is up to 50% accurate.
Increased Costs while outcomes stagnant
A recent study showed that in the USA, direct costs related to Epilepsy have almost doubled in the last decade to $28B per year, while outcomes have not improved in almost three decades.
The Potential Benefits
Improving Outcomes
Improving Quality of Life
Improving Quality of Life
By helping physicians get the data they need to make timely medical decisions.
Improving Quality of Life
Improving Quality of Life
Improving Quality of Life
Getting patients on path to seizure freedom quicker and reducing the burden of tracking seizures.
Reducing Costs
Improving Quality of Life
Reducing Costs
Helping providers and patients reduce the number of costly visits to the hospital.
The Evidence
Preliminary
We recently completed a 30 patient proof-of-concept study which resulted in robust seizure detection of the subtlest seizure type, absence seizures.
Upcoming
In July 2020, we launched an in depth clinical study involving 3 clinical collaborators that have been designated Level 4 by the National Association of Epilepsy Centers to help us collect the data we need to begin improving the accuracy of our software.
Our Team
Rachel Kuperman, MD, Founder & CEO
Rachel Kuperman, MD, Founder & CEO
Rachel Kuperman, MD, Founder & CEO
Neurologist with dual certification in epilepsy and neurology with over 10 years’ experience directing the clinical epilepsy and research programs at UCSF Benioff Children’s Hospital, Oakland
Jit Sarkar, PhD Co-Founder
Rachel Kuperman, MD, Founder & CEO
Rachel Kuperman, MD, Founder & CEO
Leads the algorithm development for Eysz solution. He completed his undergraduate degree in computer science and has deep experience applying machine learning methods. His PhD from UCSD focused on extracting signals from a complex medium.
Parth Amin, Co-Founder
Rachel Kuperman, MD, Founder & CEO
Parth Amin, Co-Founder
Leads our Product Development efforts and GTM Strategy. Brings 15+ Years Medical Device Experience in Product and Project Management, Product Launch, and Alliances having worked at Siemens Healthineers, Varian, and Omnicell.
Our Advisors
Robert Fisher, MD Scientific Advisor
Robert Fisher, MD Scientific Advisor
Robert Fisher, MD Scientific Advisor
Dr. Fisher is Maslah Saul MD Professor and Director of the Stanford Epilepsy Center. He had research awards from the Klingenstein Foundation, EF, CURE and NIH. He published 160 peer-reviewed articles and 4 books. He was named 1996-2016 in Best Doctors in America. Dr. Fisher is Past-President of the American Epilepsy Society, and has
Dr. Fisher is Maslah Saul MD Professor and Director of the Stanford Epilepsy Center. He had research awards from the Klingenstein Foundation, EF, CURE and NIH. He published 160 peer-reviewed articles and 4 books. He was named 1996-2016 in Best Doctors in America. Dr. Fisher is Past-President of the American Epilepsy Society, and has served on the Board of the ILAE and as Editor-in-Chief of the Journal, Epilepsia. His research is on new devices to treat epilepsy.
Hal Blumenfeld, MD Scientific Advisor
Robert Fisher, MD Scientific Advisor
Robert Fisher, MD Scientific Advisor
Dr. Blumenfeld's clinical and research work focuses on epilepsy, cognition and brain imaging. He directs Yale's Clinical Neuroscience Imaging Center (CNIC), a new multi-disciplinary core facility for innovative study and treatment of brain disorders. Teaching activities include a textbook titled Neuroanatomy Through Clinical Cases, Sinauer Assoc., Publ. 2002, 2010.
Peter Milford, PhD Technical Advisor
Robert Fisher, MD Scientific Advisor
Peter Milford, PhD Technical Advisor
Dr. Milford has over 15 years experience in developing high technology instrumentation. He was CTO of Eyefluence, which was developing the next generation eye-tracking wearable technology, up until October 2016, when purchased by Google. He continued to develop eye interaction and eye tracking for augmented reality (AR) and virtual real
Dr. Milford has over 15 years experience in developing high technology instrumentation. He was CTO of Eyefluence, which was developing the next generation eye-tracking wearable technology, up until October 2016, when purchased by Google. He continued to develop eye interaction and eye tracking for augmented reality (AR) and virtual reality (VR) headsets. He now serves as the President of Parallel Rules consulting firm.
Steve Duddy Business Advisor
Nicolle Napier-Ionascu Scientific Advisor
Peter Milford, PhD Technical Advisor
Steve brings 30+ years of leadership and strategy experience in the Medical Device industry. He has held a variety of leadership roles in various cross functional areas. Most recently, he is serving as the President and Chairman of Nuvolase Inc., which has developed the gold standard for Onychomycosis. Under his leadership, the company
Steve brings 30+ years of leadership and strategy experience in the Medical Device industry. He has held a variety of leadership roles in various cross functional areas. Most recently, he is serving as the President and Chairman of Nuvolase Inc., which has developed the gold standard for Onychomycosis. Under his leadership, the company has grown in revenues, remained debt-free, and has expanded into new markets.
Nicolle Napier-Ionascu Scientific Advisor
Nicolle Napier-Ionascu Scientific Advisor
Nicolle Napier-Ionascu Scientific Advisor
Practicing neuropsychology for over 12 years. She is also the head Neuropsychologist in the Epilepsy department at UCSF Benioff Children’s Hospital Oakland.
Board
Randy Berholtz JD, MBA
Randy Berholtz JD, MBA
Randy Berholtz JD, MBA
Randy leverages his corporate experience, where he has held roles as a corporate and business development executive and as general counsel, to help nurture over 25 startups in healthcare from funding, to serving as a board of director to corporate and business development and strategic initiatives. He currently services as a Partner for
Randy leverages his corporate experience, where he has held roles as a corporate and business development executive and as general counsel, to help nurture over 25 startups in healthcare from funding, to serving as a board of director to corporate and business development and strategic initiatives. He currently services as a Partner for Ventac Partners and a Senior Advisor for Mesa Partners. He is also a parent of a child with epilepsy.
James Musick, PhD
Randy Berholtz JD, MBA
Randy Berholtz JD, MBA
Dr. Musick is a Neuroscientist turned pharma executive, who brings 20+ years experience in digital technologies and pharma. He currently is the Head of Digital Transformation Neurology at UCB Biopharma, where he leads efforts to leverage digital technologies to improve existing business activities while also introducing fundamentally
Dr. Musick is a Neuroscientist turned pharma executive, who brings 20+ years experience in digital technologies and pharma. He currently is the Head of Digital Transformation Neurology at UCB Biopharma, where he leads efforts to leverage digital technologies to improve existing business activities while also introducing fundamentally new approaches which profoundly change how UCB delivers value to their customers .